Learning from past mistakes, Centrexion clears a big PhIIb hurdle for its pain drug
Jeffrey Kindler’s biotech startup Centrexion is boasting about its lead drug’s success in a Phase IIb pain study for knee osteoarthritis.
The ex-Pfizer CEO’s Boston-based biotech says that CNTX-4975, injected directly into the joint, delivered pain relief to a fairly large group of patients who had failed on first-line pain drugs, setting them up to go into a late-stage pivotal program next year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
